COMPARATIVE EFFECTS OF HYDRALAZINE ON PERFUSION OF KHT TUMOR, KIDNEY AND LIVER AND ON RENAL-FUNCTION IN MICE

被引:11
作者
HONESS, DJ [1 ]
BLEEHEN, NM [1 ]
机构
[1] UNIV CAMBRIDGE,DEPT CLIN ONCOL & RADIOTHERAPEUT,CAMBRIDGE CB2 2QH,ENGLAND
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1992年 / 22卷 / 05期
关键词
HYDRALAZINE; KHT TUMOR; BLOOD FLOW; KIDNEY; KIDNEY FUNCTION; LIVER;
D O I
10.1016/0360-3016(92)90794-I
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hydralazine has been widely used to reduce tumor blood flow in mice. It has an application in the deliberate creation of reducing environments within tumors and has been used in conjunction with both bioreductive and cytotoxic drugs. We have compared the dose-response to hydralazine of relative tissue perfusion of KHT tumor, kidney and liver, assayed by Rb-86 extraction, over the dose range 0.2 to 5.0 mgkg-1 and shown that doses of 1.0 mgkg-1 and higher cause significant reductions in perfusion of all three tissues but 0.2 mgkg-1 has no effect. Tumor perfusion (+/- 2 se) was reduced to 80 +/- 8% of control by 1.0 mgkg-1, to 38 +/- 13% by 2.5 mgkg-1 and to 35 +/- 7% by 5.0 mgkg-1. Relative kidney perfusion was reduced to 83 +/- 11% of control by 1.0 mgkg-1 and to 73 +/- 9% by 5.0 mgkg-1; relative liver perfusion was reduced to 71 +/- 10% of control by 1.0 mgkg-1 and to 64 +/- 10% by 5.0 mgkg-1. This reduction in kidney and liver perfusion may indicate that there would be impairment of elimination and/or metabolism of co-administered drugs. We have therefore also measured the dose-response of the effect of hydralazine on glomerular filtration rate and effective renal plasma flow, assayed by clearance of (EDTA)Cr-51 and I-125-iodohippurate, respectively. 5.0 mgkg-1 hydralazine blocks clearance of EDTA for 40 min, slows subsequent clearance by a factor (+/- 2 se) of 2.4 +/- 1.2, and slows I-125-iodohippurate clearance by a factor of 5.5 +/- 0.8; 1.0 mgkg-1 hydralazine slows EDTA clearance by a factor of 1.5 +/- 0.3. The time-course of the effect of 5.0 mgkg-1 hydralazine on isotope clearance was measured and this dose was shown to affect isotope clearance at times up to 4 h after administration. These data confirm that hydralazine at doses effective at reducing tumor blood flow also impairs renal function, and is therefore likely to affect the pharmacokinetics of any co-administered drug that is cleared by the kidney.
引用
收藏
页码:953 / 961
页数:9
相关论文
共 31 条
[1]   THE ENERGY-METABOLISM OF RIF-1 TUMORS FOLLOWING HYDRALAZINE [J].
BHUJWALLA, ZM ;
TOZER, GM ;
FIELD, SB ;
MAXWELL, RJ ;
GRIFFITHS, JR .
RADIOTHERAPY AND ONCOLOGY, 1990, 19 (03) :281-291
[2]   BIOREDUCTIVE DRUGS AND THE SELECTIVE INDUCTION OF TUMOR HYPOXIA [J].
BREMNER, JCM ;
STRATFORD, IJ ;
BOWLER, J ;
ADAMS, GE .
BRITISH JOURNAL OF CANCER, 1990, 61 (05) :717-721
[3]  
BROWN JM, 1987, RADIAT RES, V2, P719
[4]  
CHANTLER C, 1969, CLIN SCI, V37, P169
[6]   THE EFFECT OF HYDRALAZINE ON THE TUMOR-CYTOTOXICITY OF THE HYPOXIC CELL CYTOTOXIN RSU-1069 - EVIDENCE FOR THERAPEUTIC GAIN [J].
CHAPLIN, DJ ;
ACKER, B .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1987, 13 (04) :579-585
[8]   RENAL-FUNCTION STUDIES WITH CADRALAZINE IN CONSCIOUS DOGS - A COMPARISON WITH HYDRALAZINE [J].
FERNI, G ;
BONARDI, G ;
LOMBROSO, M ;
SEMERARO, C ;
DORIGOTTI, L .
PHARMACOLOGICAL RESEARCH, 1989, 21 (02) :211-222
[9]  
FISHER RA, 1943, STATISTICAL TABLES B
[10]   EFFECT OF PH ON HYPERTHERMIC CELL SURVIVAL [J].
FREEMAN, ML ;
DEWEY, WC ;
HOPWOOD, LE .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1977, 58 (06) :1837-1839